Send feedback

ACTA1 p.Glu336Ala

c.1007A>C · rs121909528 · VCV18288

Likely pathogenic Expert panel
Classification
Likely pathogenic
ClinVar
Review
Expert panel ★★★☆
ClinVar · 2 submitters
AlphaMissense
likely pathogenic
0.9878 · ACMG-weighted
gnomAD v4.1
Absent
absent from gnomAD v4.1
Missense predictors
3/3 damaging
AlphaMissense, REVEL, SaProt
Conditions
2
alpha-actinopathy

ClinGen expert panel — Congenital Myopathies VCEP

Likely Pathogenic for alpha-actinopathy. Applied ACMG criteria (verbatim):

PP4_Moderate PM2_Supporting PP1_Moderate PP2 PP3

Curation rationale (ClinGen, verbatim)

The c.1007A>C (NM_001100.4(ACTA1):c.1007A>C (p.Glu336Ala)) variant in ACTA1 is a missense variant predicted to cause substitution of glutamate by alanine at amino acid 336 (p.Glu336Ala). This variant is absent from gnomAD v4.1.0 (PM2_Supporting). ACTA1, in which the variant was identified, is defined by the ClinGen Congenital Myopathies VCEP as a gene that has a low rate of benign missense variation and where pathogenic missense variants are a common mechanism of disease (PP2). The computational predictor REVEL gives a score of 0.874, which is above the threshold of 0.7, evidence that correlates with impact to ACTA1 function (PP3). At least one patient with this variant displayed cores and fiber type disproportion on muscle biopsy, which is highly specific for actin accumulation myopathy (PP4_Moderate, PMID: 15520409). This variant has been reported in 5 individuals from one family with muscle weakness (PP1_Moderate; PMID: 15520409). In summary, this variant meets the criteria to be classified as likely pathogenic for autosomal dominant alpha-actinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen Congenital Myopathies VCEP: PM2_Supporting, PP2, PP3, PP4_Moderate, PP1_Moderate (Congenital Myopathies VCEP Specifications Version 2.0; July 8, 2024).

ClinGen Evidence Repository → · reported verbatim, not re-tallied by Sugi Variant.

Computational evidence

Protein change
AlphaMissense0.9878likely pathogenic ✓ concordant with ClinVar
REVEL0.874moderately pathogenic-leaning
SaProtLLR -13.15damaging
⇒ AlphaMissense, REVEL and SaProt all call this damaging.
Splicing
SpliceAI—not assessed · no allele here is in the release
Constraint at this position
ConservationphyloP 6.1GERP 1.5, phastCons 1
Regional constrainto/e 0.33constrained · MANE · 1,613 bp · p 1.6e-54 · regional, not allelic
Overall
CADD27.2PHRED · no single calibrated threshold — expert panels disagree

AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.

Population frequency

gnomAD v4.1 · exomes + genomes

Absent from gnomAD v4.1. Not observed in any sequenced alleles — a rarity signal (ACMG PM2-supporting), not evidence of pathogenicity on its own.

Variant & gene context

Gene
ACTA1
Protein
p.Glu336Ala
Coding
c.1007A>C
MANE Select
NM_001100
dbSNP
rs121909528
Type
single nucleotide variant
Location
chr1:229431626 (GRCh38)
Gene constraint
LOEUF 0.931 · pLI <0.01 (gnomAD)
Structure
AlphaFold pLDDT 95.21 · 5 PDB
Residue 336
a UniProt-annotated variant site (in cmyo2a)
Full ACTA1 gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Similar variants

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/acta1-p-glu336ala (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown